Interim Report, January - March 2007

Interim Report, January - March 2007

-Net revenues amounted to MSEK 6.4 (50.3) 
-The loss after tax was MSEK 37.9 (profit: 15.3)
-Earnings per share amounted to a loss of SEK 2.73 (profit: 1.15)

KEY EVENTS DURING THE FIRST QUARTER OF 2007 
-Orexo strengthens organization - Christina Rångemark Åkerman appointed Head of
Technology and Product Development
-FDA approves Orexo's application (IND) to complete Phase III study program for
the insomnia product Sublinox™ (OX 22)

KEY EVENTS AFTER THE CLOSE OF THE PERIOD
-On April 23, Orexo held its Annual General Meeting - the Board of Directors was
re-elected
-Orexo receives patent approval for OX 17

For report in full format, see enclosed link to pdf. 


For more information, please contact 
Zsolt Lavotha, President & CEO, Tel: +46 (0)18-780 88 12, e-mail:
zsolt.lavotha@orexo.se 

Claes Wenthzel, Executive Vice President and CFO, Orexo AB 
+46 (0)18 780 88 44, +46 (0)708-62 01 22, e-mail: claes.wenthzel@orexo.se 

To the editors 

About Orexo 
Orexo is a pharmaceutical company that focuses on developing new pharmaceutical
drugs within areas currently subject to considerable clinical needs. Orexo´s
products are based on existing pharmaceuticals and the company´s patented
drug-delivery technologies. Orexo applies its broad expertise in medicine and
pharmacy to the further development of existing pharmaceutical substances. By
combining well-documented compounds with its own patented drug-delivery methods
and its unique expertise in dry formulations (for example, tablets), Orexo is
able to develop new patented pharmaceuticals. 

At present, the company has two products on the market, three projects in late
clinical phase - one of which has been out-licensed in the US, Europe and Japan
and submitted for registration in Europe - and two projects in the
pharmaceutical formulation phase. Orexo has an active intellectual property
rights strategy and an extensive patent portfolio to protect its products and
technologies. 

Orexo is listed on the OMX Nordic List Mid Cap (ticker: ORX). 
www.orexo.com